Pharmaceutical composition dentoferon in form of gel for preventing and treating periodontal diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to dentistry, and concerns preparations for preventing and treating the diseases of periodontal membrane and oral mucosa. That is ensured by using a pharmaceutical composition in the form of a gel which contains metronidazole benzoate, chlorhexidine gluconate as an active substance and additionally the ingredients specified in a group of alpha-, beta-, gamma-, recombinant interferon.

EFFECT: invention provides reducing the length of treatment in the patients with inflammatory periodontal diseases due to the wide spectrum of action of the composition, prolonged fixation on gums, which accelerates the regeneration of the oral mucosa.

2 cl, 5 ex

 

The invention relates to medicine, namely to the dentist, and applies to medicines for the prevention and treatment of infectious-inflammatory diseases of the periodontium, in particular drugs for the prevention and treatment of periodontal disease.

Widely known pharmaceutical compositions for the prevention and treatment of periodontal disease in the form of pastes, elixirs, mouthwashes, ointments, emulsions and gels. In the treatment of periodontal disease adhere to three main etiological directions adverse effects: antibacterial, anti-inflammatory, regenerating, which eliminates the source of infection, stops inflammation in the affected area, improving the processes of trophic and regeneration.

Known composition for the treatment of inflammatory periodontal diseases (EN 2228168, 2004), containing thymol, sodium fluoride, fenilsalitsilat, eugenol, clove oil, sage oil, peppermint oil. The disadvantage of this composition is a weak antibacterial effect due to the low bactericidal activity of the oils included in its composition.

Known composition (EN 2201206, 2002) for the treatment of periodontal disease containing an aqueous extract of eucalyptus, soybean oil, distilled monoglycerides, higher fatty alcohols, stearin cosmetic, propylene glycol, nipagin, peppermint oil, al is a-tocopherol acetate, the concentrate Pro-coniferous, purified water. The disadvantage of this composition is a weak anti-inflammatory effect that reduces the effectiveness of treatment and quick removal of the major symptoms of periodontal disease, such as bleeding and hypersensitivity of teeth.

Known composition for the local treatment of periodontal disease and mucous in the patent (RU 2190995, 2002). The composition contains tinctures of chamomile and calendula, rosehip extract, sangviritrin, biopolymer based (2% acetic acid solution of collagen and alginate sodium) and water. The disadvantage of this composition is very weak direct anti-inflammatory effect.

Known composition for the prevention of periodontal disease and the oral mucosa of the mouth containing water, ethyl alcohol, fragrance, menthol, alcohol-glycerin plantain extract, mineral and vitamin concentrate kelp in combination with polyvinylpyrrolidone, sodium lauryl sulphate and antiseptic-preservative (EN 2005465, 1994).

You know the "Geologist" prolonged action for the treatment of inflammatory diseases of the oral cavity that contains an antiseptic substance chlorhexidine digluconate, polysaccharide - sodium salt of hyaluronic acid, Chlorobenzilate alcohol, glycerin, peppermint odorant and distilled water. The tool which may be prepared in the form of a solution for washing and irrigation. The tool may further comprise a gelling agent that represents polyvinyl alcohol in combination with sodium alginate, in this case, it is prepared in gel form, the tool can optionally contain metronidazole (EN 2286764, 2006).

It is known for the treatment of periodontal diseases, which contains metronidazole, rutin, polyethylene glycol 1500 and 400, glycerol and water in a quantitative content (EN 2322227, 2008).

It is known for the treatment of periodontal disease containing as an active substance of plant origin dry extract of black currant leaves, water, glycerin, water-soluble derivative of cellulose, calcium glycyrrhizinate, sodium fluoride, sodium salt of propyl paraben, fructose, peppermint oil with a content of components (EN 2361600, 2009).

It is known tool for local treatment of periodontal disease and the mucous membranes of the oral cavity, which can be used in complex conservative therapy in the treatment of inflammatory periodontal diseases, including gingivitis and periodontitis, as well as in traumatic injuries of the mucous membranes of the oral cavity (thermal, mechanical). This tool contains lincomycin, metronidazole, as a gel base silicone glycerokinase SOS is ava Si(C 3H7O3)4·6C3H8O3·24H2O, lidocaine hydrochloride, and dexamethasone in the following ratio of components, wt.%: metronidazole 0,5-1,0, lincomycin 0,5-1,0, lidocaine hydrochloride, 10%solution of 5.0-7.0, dexamethasone, a 0.4%solution of 2.50-3.75 to, silicone glycerokinase else (EN 2383337, 2010).

Known pharmaceutical heisteria composition for local and external use containing the active substance and the carrier at a certain ratio of components, at the same time as the media it contains glycerokinase based solvatochromism of glycerate silicon and titanium, and for the treatment of infectious-inflammatory diseases of the mucous membranes of the oral cavity as active substance, a mixture of pefloksatsina, metronidazole and chlorhexidine digluconate in the form of a 20%solution, for the treatment of inflammatory periodontal diseases and traumatic lesions of the mucous membranes of the oral cavity as active substance, a mixture of lincomycin, metronidazole and dexamethasone, and, optionally, lidocaine hydrochloride (EN 2417102, 02.05.2012,).

Known dental gel for the treatment and prevention of infectious-inflammatory diseases of the oral cavity "Metrogyl dent", containing metronidazole, chlorhexidine gluconate in the form of a 20%aqueous process is a and the base, composed of propylene glycol, carbomer-940, disodium edetate, sodium saccharin, levomenthol, sodium hydroxide and water (grudanov A.I., Dmitrieva N.A., Ovchinnikov V.V. Dependence of antimicrobial efficacy "Metrogylum dent" on the duration of the local introduction in inflammatory lesions of periodontal // Periodontics. - 2001. No. 1-2 (19-20). - P.32-36). However, therapeutic effect of metronidazole and chlorhexidine antibacterial and anti-inflammatory effects on the gums, but does not regenerating and antioxidant action.

Known dental gel for the treatment of inflammatory diseases of the oral cavity, containing metronidazole, oximetery, a copolymer of styrene with maleic anhydride, glycerin, water in certain proportions (EN 2226383, 2004).

Known gel composition for treatment of dental diseases, containing diclofenac and chlorhexidine, mucoadhesive agent, a gelling agent and a pharmaceutically acceptable diluent in a quantitative content (EN 2288699, 2006).

The closest in composition and the result achieved by the claimed technical solution is a composition in the form of an aqueous gel for the treatment of dental diseases. This composition is made in the form of an aqueous gel, which contains Amigo metronidazolesta, chlorhexidine, local anesthetic, glioblastome agent, water, chelate forming agent, a sweetener, mucoadhesive polymer, flavoring agent and pH modifier. Components take in a quantitative content (EN 2242963, 2004). The disadvantage of this arrangement is that it is not effective enough.

Object of the invention is the creation of a more effective dental gel composition, due to its regenerating, anti-inflammatory, immunomodulatory, antibacterial action with a long fixation on the gums, contributing to prolonged action of the claimed composition.

The technical result of the invention is the reduction of terms of treatment of patients with inflammatory periodontal disease due to the wide spectrum of the composition, long-term lock on the gums and accelerates the regeneration of the mucous membranes of the oral cavity.

To achieve the technical result of the pharmaceutical composition in the form of gel for the prevention and treatment of periodontal disease containing metronidazolesta, chlorhexidine as active-active ingredient, carbomer and hypromellose as a gelling agent, menthol as a flavoring, a sweetener, the disodium salt of EDTA as a VSP the service component and grease-forming base, according to the invention it further comprises as active-active substance components, selected from the group of alpha-or beta-, or gamma-interferon, lysine, Proline, choline salicylate, as a sweetener contains saccharin or sorbitol, and as grease-forming framework contains components selected from the group of glycerin, polyethylene glycol 400, polyethylene glycol 4000, propylene glycol, glycerin, purified water in the following ratio of components in wt.%:

alpha or beta, or gamma recombinant

interferon, ME1000-1000000
metronidazolestaof 0.01 to 10.0
chlorhexidine0,01-1,0
lysine0,1-10,0
Proline0,1-10,0
holinsalicilata0,1-10,0
the disodium salt of EDTA0,001-0,1
sorbitol or saccharin0,1-10,0
menthol0,1-1,0
carbomer0.5 to 5.0
the hypromellose0.1 to 5.0
grease-forming baserest

In addition, as an auxiliary component composition further comprises triethanolamine in the amount of 0.5-5.0 wt.%.

Spent an analysis of the prior art, including searching by the patent and scientific and technical information sources, and identify sources that contain information about the equivalents of the claimed pharmaceutical compositions, has allowed to establish that the petitioners have not found a similar, characterized by signs, identical to all the essential features of the claimed pharmaceutical compositions.

The definition from the list of identified unique prototype allowed us to identify a set of essential in relation to perceived technical result of the distinctive features in the claimed pharmaceutical compositions set forth in the claims.

Therefore, the claimed pharmaceutical composition meets the criterion of "novelty."

For verification of the compliance of the pharmaceutical composition, the applicants conducted an additional search of the known solutions to identify signs, showpad the matter of the distinctive features of the prototype features of the claimed invention.

The search results showed that the claimed invention not apparent to the expert in the obvious way from the prior art, certain applicants have identified no impact envisaged the essential features of the claimed pharmaceutical compositions of transformations to achieve a technical result.

Therefore, the claimed invention meets the criterion of "inventive step".

The criteria of the invention "industrial applicability" is confirmed by the fact that the claimed pharmaceutical composition having regenerating, anti-inflammatory, immunomodulatory, antibacterial effect with prolonged fixation on the gums, contributing to prolonged action of the claimed compositions of matter can be successfully used for the treatment of infectious-inflammatory diseases of the periodontium.

The invention is illustrated by examples.

Example 1

The preparation of the claimed medicinal products carry a standard method of preparation of gels by mixing all members of the tool components to obtain a homogeneous mass, characterizing the gel turbid white viscous consistency density of 1.3 g/cm3, a pH of 6.2 to 6.5. The obtained gel meets the requirements of a pharmaceutical agent for topical application.

the finished the product Packed in the required capacity (for example, tubes), seal and label.

To obtain the gel mix the following components of the claimed pharmaceutical compositions in wt.%:

alpha-interferon ME1000
metronidazolesta10,0
chlorhexidine0,01
lysine10,0
the disodium salt of EDTA0,1
sorbitol10,0
menthol1,0
carbomer5,0
the hypromellose5,0
grease-forming basethe rest is up to 100.

Example 2

Carried out analogously to example 1.

To obtain the gel mix the following components of the claimed pharmaceutical compositions in wt.%:

beta-interferon ME10000
metronidazolesta0,01
chlorhexidine0,1
Proline0,1
the disodium salt of EDTA0,001
saccharin0,1
menthol0,1
carbomer0,5
the hypromellose0,1
triethanolamine0,5
grease-forming basethe rest is up to 100.

Example 3

Carried out analogously to example 1.

To obtain the gel mix the following components of the claimed pharmaceutical compositions in wt.%:

gamma-interferon ME10000
metronidazolesta5,0
chlorhexidine0,5
holinsalicilata5,0
the disodium salt of EDTA0,5
sorbitol5,0
menthol0,5
carbomer2,5
the hypromellose3,0
grease-forming basethe rest is up to 100.

Example 4

Carried out analogously to example 1.

To obtain the gel mix the following components of the claimed pharmaceutical compositions in wt.%:

alpha-interferon ME100000
metronidazolesta2,5
chlorhexidine1,0
lysine0,1
Proline10,0
holinsalicilata10,0
the disodium salt of EDTA0,001
saccharin01
menthol1,0
carbomer2,5
the hypromellose2,0
grease-forming basethe rest is up to 100.

Example 5

Carried out analogously to example 1.

To obtain the gel mix the following components of the claimed pharmaceutical compositions in wt.%:

beta-interferon ME1000000
metronidazolesta0,01
chlorhexidine0,01
lysine0,1
Proline0,1
the disodium salt of EDTA0,01
sorbitol5,0
menthol2,5
carbomer0,3
the hypromellose 1,0
grease-forming basethe rest is up to 100.

For the evaluation of therapeutic action proposed pharmaceutical compositions were tested. The composition was used for the treatment and prevention of acute and chronic periodontal disease and mucous membranes of the oral cavity in patients undergoing outpatient treatment. Depending on the method of treatment of patients aged from 25 to 40 years of age of different sexes were divided into primary (10) and control group prototype (10 people). The proposed and known composition was used in the form of applications on the affected area. The treatment time was 8-10 days. Clinical effects in the study group appeared after 2 days from the start of treatment and resulted in rapid relief of signs of inflammation, early scarring periodontal pockets, stopping bleeding gums after 3 days, the elimination of tooth mobility of the first degree and the second reduction after 10 days. Patients of the control group, the clinical effect was observed after 15 days.

All patients underwent medical examination. Assessment of efficacy was based on subjective and objective data and the dynamics of clinical observations.

When assessing the subjective opinions of the patients noted the good effect, side effects were not observed. When evaluating the results of clinical observations confirmed the fact of the symptoms that occur when periodontal diseases.

Thus, the proposed arrangement not only allows you to extend the range of products for the treatment of periodontal disease and oral mucosa, but also to reduce the duration of treatment due to the high therapeutic effect, due to the wide range of actions, namely, regenerative, anti-inflammatory, immunomodulatory, antibacterial effect with prolonged fixation on the gums, contributing to prolonged action of the claimed composition.

1. Pharmaceutical composition in the form of gel for the prevention and treatment of periodontal disease containing metronidazolesta, chlorhexidine as actively active ingredient, carbomer and hypromellose as a gelling agent, menthol as a flavoring, a sweetener, the disodium salt of EDTA as an auxiliary component and grease-forming base, characterized in that it further comprises as an active substance components, selected from the group of alpha-or beta-, or gamma-interferon, lysine, Proline, choline salicylate, as podslastitel which contains saccharin or sorbitol, and as grease-forming framework contains components selected from the group of glycerin, polyethylene glycol 400, polyethylene glycol 4000, propylene glycol, glycerin, purified water in the following ratio, wt.%:

alpha, or beta, or
gamma-interferon ME1000-1000000
metronidazolestaof 0.01 to 10.0
chlorhexidine0,01-1,0
lysine0,1-10,0
Proline0,1-10,0
holinsalicilata0,1-10,0
the disodium salt of EDTA0,001-0,1
sorbitol or saccharin0,1-10,0
menthol0,1-1,0
carbomer0.5 to 5.0
the hypromellose0.1 to 5.0
grease-forming base rest

2. The pharmaceutical composition according to claim 1, characterized in that as an auxiliary component further comprises triethanolamine in the amount of 0.5-5.0 wt.%.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dentistry, and may be used for local therapy of inflammatory periodontal diseases. That is ensured by the daily applications of powdered cellulose surgical cotton on a dentogingival edge after curettage to normalise the microcirculation and hemodynamic values.

EFFECT: method provides higher clinical effectiveness in periodontal diseases, reduced complications and disability periods due to normalising the free radical levels in the damaged tissue while reducing inflammation and accelerating the process of epithelialisation of periodontal tissues.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and methods of such compositions application. Claimed composition for oral cavity care contains amorphous quartz and source of ions of bivalent tin, with average size of amorphous quartz particles constituting from 1 to 20 microns. Version of composition additionally includes one or more essential oils and chelant. Method of oral cavity care includes stage, at which upper said composition is introduced into subject's oral cavity.

EFFECT: application of amorphous quartz (fuse quartz) as abrasive in mixture of composition for oral cavity care ensures good compatibility with ions of bivalent tin with effective and safe cleaning of dental tissues.

17 cl, 2 ex, 30 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to composition for oral cavity care and methods of its application. Claimed is composition for oral cavity care, which contains: arginine, in free form or in form of salt in amount from 0.1 to 20 wt % of total composition weight; triclosan in amount from 0.01 to 5 wt % of total composition weight; anionic polymer, which is a copolymer of methyl vinyl ether and maleic anhydrate; anionic surfactant in amount from 0.01 to 10 wt % of total composition weight; soluble fluoride salt in amount from 0.01 to 2 wt % of total body weight, in order to provide 50-25000 ppm of weight of fluoride ions, in which soluble fluoride salt or source of fluoride ions is selected from sodium fluoride, sodium monofluorophosphate and their mixtures; and abrasive material, which contains fraction of minor particles, constituting at least about 5 wt % of total composition weight, and in said fraction minor particles have average diameter d50 smaller than 5 mcm.

EFFECT: application of composition for oral cavity care along with improved delivery of antibacterial agent provides additional advantages in acceleration of remineralisation and restoration of precarious affection foci due to combination of fluoride and arginine, as well as due to application of finely disperse abrasive as composition component.

11 cl, 1 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and to methods of their application. Claimed are compositions for oral cavity care, which contain effective amounts of arginine in free or salt form, anionic surface active substance, halogenated diphenyl ether, anionic polymer, and precipitated calcium carbonate, which has d50 from approximately 0.5 to approximately 3 micrometres.

EFFECT: compositions are efficient, in particular, for reduction of bacteria adherence to tooth surface in subject's oral cavity, in addition, chemical composition provides favourable effect in activation of remineralisation, elimination of pre-caries damage and strengthening healthy state of oral cavity along with intensification of taste properties of formulation of preparation for oral cavity care and increase of general acceptability pf product for consumers.

33 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapeutic dentistry, and is intended for treatment of pulpitis, apical and marginal dental periodontitis. Drug processing of root canal is carried out. Canal is dried. After that, root canal of tooth is filled with liquid No 1 - solution of subacid magnesium fluoric silicate from composition of "Dentin-hermetising liquid". Active needle electrode of device for carrying out electro- or depot phoresis is introduced into canal and transcanal electrophoretic introduction of ions, contained in liquid, into dentin tubes of tooth root is performed. Amount of electricity, passing through tissues of tooth root tissues, constitutes from 1 to 5 mA X min, with current value from 0.1 to 1 mA. After that root canal is dried with air and electrophoresis of liquid No 2 - alkaline suspension of highly-dispersive calcium hydroxide from composition "Dentin-hermetising liquid" is carried out at the same parameters as the first liquid. Root canal is dried with air and filled by traditional method.

EFFECT: method makes it possible to reduce number of complications and increase efficiency of treatment of pulpitis, apical and marginal periodontitis due to deep transcanal electrophoretic fluoridation of tooth root dentin.

7 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapeutic dentistry, and can be used in treatment of deep dental caries. For this purpose preparation of caries cavity with its further antiseptic processing with ozone-oxygen mixture possessing high bactericidal effect is carried out. Ozone concentration in mixture constitutes 30-40 mcg/ml. Processing is carried out for 25-40 seconds. After that, self-hardening radiopaque material, containing calcium hydroxide "Life" is used as medicinal padding and filling is performed.

EFFECT: method makes it possible to perform tooth filling during the first visit due to antiseptic processing not only on the surface of caries cavity, but in dentin tubes.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely therapeutical stomatology and may be used for treating the patients suffering generalised periodontitis. That is ensured by periodontal care and antiseptic preparation, topical treatment with "Lesnoy Balsam" involving applications to a region of inflammation in an amount of 0.05-0.2 g and introduction into gingival pockets. Length of the procedures is 15 minutes twice a day; the therapeutic course is 5-6 days: the general treatment includes the preparation "Ginkoum" 1 capsule three times a day; the therapeutic course is 5 weeks.

EFFECT: invention enables a high therapeutic effect by blocking pathogen flora, improved regional gingival haemodynamics, wound healing and epithelising actions, reduced perivascular oedema and vascular metabolic improvements with no discomfort to the patient.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is presented is a compound for preparing an oral rinse for treating radio-induced xerostomia in the following proportions of the ingredients in water 200 ml: ethyl cellulose 0.5 - 0.9 g, calcium hydrophosphate 0.1 - 0.3 g, potassium hydrophosphate as a buffer system 0.4 - 0.6 g, succinic acid 0.10 - 0.14 g.

EFFECT: invention provides the improved clinical effectiveness in radio-induced xerostomia ensured by the recovered physical-chemical properties of saliva and normalised processes of solid tissue mineralisation.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgical dentistry and physiotherapy, and may be used in dental implantology for preventing postoperative infectious-inflammatory complications following bone tissue surgeries. For this purpose, the surgical intervention is followed by blood sampling from an incisional wound to be treated with ozonised gas of the ozone concentration of 20±2 mg/l. Then blood is mixed with a bone autograft and treated with ozonised gas of the ozone concentration of 20±2 mg/l. The prepared autograft is introduced into an implantation and sinus lifting site. From the second postoperative day, the incisional field is exposed to extremely high frequency for 3-6 days for 10-20 minutes. For 5-7 days, the incisional field is treated with ozonised distillate of the ozone concentration of 1-2 mg/l.

EFFECT: method enables effective prevention of postoperative infectious-inflammatory complications by improving osteogenesis and accelerating implant integration ensured by the ozone treatment in specific regimen and environment.

3 cl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to dual tooth brushing compositions and methods for using them. The presented dental care composition contains a first ingredient containing a calcium source in the form of dicalcium phosphate, a second ingredient containing at least one anion source wherein one of the anion sources represents a fluorine ion source wherein at least the second ingredient contains arginine or its salt with the first and second ingredient are separated from each other until supplied and combined for dental application. There are also presented a method of oral care and a method of elimination or relief of discomfort and pain related to dentine hypersensitivity with the use of said composition.

EFFECT: formulation of the first and second ingredients provides the composition storage stability, as well as oral delivery of the high concentrations of all the active agents that enables implementing such favourable effects, as a lower probability of erosion and caries, lower enamel hypersensitivity.

16 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, in particular to dentistry, and deals with application of preparation for removal of teeth coloration. Claimed is tooth brush of definite construction, on whose head placed is composition, containing small quantities of highly cleaning abrasive materials with comparatively small size and non-containing any other active components for oral cavity care. Claimed capsulated composition contains orally acceptable carrier and from 1% to 10 wt % of abrasive material in such a way, that total quantity of abrasive material, supplied at one application, constitutes from 2 to 8 mg. Abrasive material has medium size of particles within the interval from 3 to 7 mcm, at least, with 90 wt % of particles with size smaller than 16 mcm. Also claimed is method of claimed composition production and method of removal of teeth coloration with said composition.

EFFECT: invention ensures effective removal of teeth coloration without application of other active components for oral cavity care.

27 cl, 14 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, in particular to dentistry, and deals with application of preparation for removal of teeth coloration. Claimed is tooth brush of definite construction, on whose head placed is composition, containing small quantities of highly cleaning abrasive materials with comparatively small size and non-containing any other active components for oral cavity care. Claimed capsulated composition contains orally acceptable carrier and from 1% to 10 wt % of abrasive material in such a way, that total quantity of abrasive material, supplied at one application, constitutes from 2 to 8 mg. Abrasive material has medium size of particles within the interval from 3 to 7 mcm, at least, with 90 wt % of particles with size smaller than 16 mcm. Also claimed is method of claimed composition production and method of removal of teeth coloration with said composition.

EFFECT: invention ensures effective removal of teeth coloration without application of other active components for oral cavity care.

27 cl, 14 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition and to application of combination, which contains one or several polycosanols, tocotrienol and/or lycopene, one or several procyanidole oligomers and vegetable oil, enriched with ω - 3, ω - 6 unsaturated fatty acids for preparing such compositions.

EFFECT: combination of said components makes it possible to reduce level of cholesterol and triglycerides in blood, strengthen and protect walls of arteries.

19 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a cardioprotective and antioxidant drug. The cardioprotective and antioxidant drug prepared by the three-staged extraction of ground tick trefoil (Hedysarum alpinum) herb in aqueous-alcoholic solutions to be randomly agitated at room temperature in a blacked-out place under certain circumstances; then the fractions are poured out and dried in a thermostat.

EFFECT: drug prepared by the above method possesses no side action and shows manifested cardioprotective and antioxidant action.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing a milk thistle extract having a higher degree of silymarin release. A method for preparing a milk thistle extract, wherein the extract containing 15-85 wt %, particularly 30-65 wt % of silymarin is treated with anhydrous C1-C4 alcohol, optionally filtered and concentrated, then dried and optionally ground, wherein a degree of silymarin release is 80% or higher (versions). The milk thistle extract for treating and preventing liver and gallbladder dysfunctions. A pharmaceutical composition for treating and preventing liver and gallbladder dysfunctions.

EFFECT: extract is characterised by a higher degree of silymarin release and effective for treating and preventing the liver and gallbladder dysfunctions.

8 cl, 3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preventing a foetus pathology in pregnant women suffering acute respiratory viral infections. That is ensured by the vitamin therapy according to the daily dosages. The therapy is combined with the additional antihomotoxic therapy with the preparation Traumel C 2.2 ml intravenously every second day over a period of the clinical manifestations of the ARVI, and with the preparation Engystol for 6 weeks from the beginning of the disease - 1 tablet 3 times a day for the first 2 weeks. Then 1 tablet is taken 2 times a day for the following 2 weeks. Then 1 tablet is taken 1 time a day for the last 2 weeks.

EFFECT: method is safe for the pregnant woman's and foetus's health; it is available, provides the more effective prevention of a perinatal pathology caused by the acute respiratory viral infection in the women during gestation.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preventing a foetus pathology in pregnant women suffering acute respiratory viral infections. That is ensured by the vitamin therapy according to the daily dosages. The therapy is combined with the additional antihomotoxic therapy with the preparation Traumel C 2.2 ml intravenously every second day over a period of the clinical manifestations of the ARVI, and with the preparation Engystol for 6 weeks from the beginning of the disease - 1 tablet 3 times a day for the first 2 weeks. Then 1 tablet is taken 2 times a day for the following 2 weeks. Then 1 tablet is taken 1 time a day for the last 2 weeks.

EFFECT: method is safe for the pregnant woman's and foetus's health; it is available, provides the more effective prevention of a perinatal pathology caused by the acute respiratory viral infection in the women during gestation.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preventing a foetus pathology in pregnant women suffering acute respiratory viral infections. That is ensured by the vitamin therapy according to the daily dosages. The therapy is combined with the additional antihomotoxic therapy with the preparation Traumel C 2.2 ml intravenously every second day over a period of the clinical manifestations of the ARVI, and with the preparation Engystol for 6 weeks from the beginning of the disease - 1 tablet 3 times a day for the first 2 weeks. Then 1 tablet is taken 2 times a day for the following 2 weeks. Then 1 tablet is taken 1 time a day for the last 2 weeks.

EFFECT: method is safe for the pregnant woman's and foetus's health; it is available, provides the more effective prevention of a perinatal pathology caused by the acute respiratory viral infection in the women during gestation.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preventing a foetus pathology in pregnant women suffering acute respiratory viral infections. That is ensured by the vitamin therapy according to the daily dosages. The therapy is combined with the additional antihomotoxic therapy with the preparation Traumel C 2.2 ml intravenously every second day over a period of the clinical manifestations of the ARVI, and with the preparation Engystol for 6 weeks from the beginning of the disease - 1 tablet 3 times a day for the first 2 weeks. Then 1 tablet is taken 2 times a day for the following 2 weeks. Then 1 tablet is taken 1 time a day for the last 2 weeks.

EFFECT: method is safe for the pregnant woman's and foetus's health; it is available, provides the more effective prevention of a perinatal pathology caused by the acute respiratory viral infection in the women during gestation.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing a chromogenic complex of red belt fungus. A method for preparing a chromogenic complex of red belt fungus involving the three-staged extraction of a ground fruiting body of red belt fungus in an aqueous solution of sodium hydroxide, herewith the first-stage extract and pulp are prepared at first; then the pulp is extracted to prepare the second-stage extract; the first-stage and second-stage extracts are combined, and the chromogenic complex is deposited by adding hydrochloric acid to the combined extract under certain conditions.

EFFECT: method enables providing higher yield of the end product having higher antioxidant activity.

1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating viral hepatites. Treating viral hepatites involves the interferon therapy. An interferon therapy session is conducted by inhalations of a gas mixture of xenon and oxygen in the concentration of 50:50 to observe the signs of gas exposure - faintness, nystagmus, paresthesia, hyperemia of face, euphoria. The gas mixture is inhaled every second day for 1 month.

EFFECT: invention enables reducing the number of therapeutic complications that is ensured by prevention of stress and depression.

4 cl, 4 ex

Up!